Literature DB >> 2448320

The suppression of malignancy by terminal differentiation: evidence from hybrids between tumour cells and keratinocytes.

H Harris1, M E Bramwell.   

Abstract

When malignant human cells are crossed with diploid human keratinocytes, malignancy, as defined by progressive growth in vivo, is suppressed so long as the hybrid cells continue to produce involucrin, a protein that characterizes terminal differentiation in the keratinocyte. When, on continued cultivation in vitro, the cells lose the ability to produce involucrin, they reacquire the ability to grow progressively in the animal.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2448320     DOI: 10.1242/jcs.87.3.383

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  5 in total

1.  Tumor suppression by collagen XV is independent of the restin domain.

Authors:  Michael J Mutolo; Kirsten J Morris; Shih-Hsing Leir; Thomas C Caffrey; Marzena A Lewandowska; Michael A Hollingsworth; Ann Harris
Journal:  Matrix Biol       Date:  2012-04-16       Impact factor: 11.583

2.  Complete suppression of tumor formation by high levels of basement membrane collagen.

Authors:  Ann Harris; Henry Harris; Michael A Hollingsworth
Journal:  Mol Cancer Res       Date:  2007-12       Impact factor: 5.852

3.  Effects of granulation tissue conditioned medium on the in vitro differentiation of keratinocytes.

Authors:  C C Huang; Z X Yi; W Y Chao
Journal:  Arch Otorhinolaryngol       Date:  1988

4.  Transformed human bronchial epithelial cells (BEAS-2B) alter the growth and morphology of normal human bronchial epithelial cells in vitro.

Authors:  C D Albright; R T Jones; E A Hudson; J A Fontana; B F Trump; J H Resau
Journal:  Cell Biol Toxicol       Date:  1990-10       Impact factor: 6.691

5.  The conversion of mouse skin squamous cell carcinomas to spindle cell carcinomas is a recessive event.

Authors:  A B Stoler; F Stenback; A Balmain
Journal:  J Cell Biol       Date:  1993-09       Impact factor: 10.539

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.